| Equity in the delivery of health care in Europe and the US E Van Doorslaer, A Wagstaff, H Van der Burg, T Christiansen, ... Journal of health economics 19 (5), 553-583, 2000 | 838 | 2000 |
| A typology for provider payment systems in health care M Jegers, K Kesteloot, D De Graeve, W Gilles Health policy 60 (3), 255-273, 2002 | 330 | 2002 |
| Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries A Ament, R Baltussen, G Duru, C Rigaud-Bully, D De Graeve, Å Örtqvist, ... Clinical Infectious Diseases 31 (2), 444-450, 2000 | 192 | 2000 |
| The distributional impact of health financing in Europe: A review D De Graeve, T Van Ourti World Economy 26 (10), 1459-1479, 2003 | 78 | 2003 |
| Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis D De Graeve, A Smet, A Mehnert, S Caleo, H Miadi-Fargier, ... Pharmacoeconomics 23, 35-47, 2005 | 71 | 2005 |
| Supplemental health insurance and equality of access in Belgium E Schokkaert, T Van Ourti, D De Graeve, A Lecluyse, C Van de Voorde Health economics 19 (4), 377-395, 2010 | 62 | 2010 |
| Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium A De Ridder, D De Graeve Clinical drug investigation 26, 75-90, 2006 | 62 | 2006 |
| Economic aspects of pneumococcal pneumonia: a review of the literature D De Graeve, P Beutels Pharmacoeconomics 22, 719-740, 2004 | 44 | 2004 |
| Direct costs of health care for HIV/AIDS patients in Belgium RC Decock, AME Depoorter, DD Graeve, R Colebunders AIDS care 13 (6), 721-731, 2001 | 39 | 2001 |
| The economics of health insurance in low and middle-income countries D De Graeve | 38 | 1999 |
| Experience: the most critical factor in choosing after-hours medical care H Philips, D Mahr, R Remmen, M Weverbergh, D De Graeve, ... Quality and Safety in Health Care 19 (6), e3-e3, 2010 | 34 | 2010 |
| Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium D De Graeve, G Lombaert, H Goossens Pharmacoeconomics 17, 591-601, 2000 | 31 | 2000 |
| Evaluatie van de effecten van de maximumfactuur op de consumptie en financiële toegankelijkheid van gezondheidszorg E Schokkaert, J Guillaume, A Lecluyse, H Avalosse, K Cornelis, ... | 21 | 2008 |
| Drug eluting stents in Belgium: health technology assessment M Neyt, H van Brabandt, S Devriese, J Mahieu, A De Ridder, ... | 20 | 2007 |
| Disease burden and medical cost-analysis of Acute Respiratory Infections in a low-income district of Bogotá CA Lara-Oliveros, D De Graeve, F Franco, SP Daza Revista de Salud Pública 18, 568-580, 2016 | 19 | 2016 |
| Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach A De Ridder, D De Graeve Pharmacoeconomics 27, 69-80, 2009 | 19 | 2009 |
| Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium L Annemans, R Crott, D Degraeve, D Dubois, M Huybrechts, F Peys, ... Pharmacy World and Science 24, 5-7, 2002 | 19 | 2002 |
| Predicting the place of out-of-hours care—a market simulation based on discrete choice analysis H Philips, D Mahr, R Remmen, M Weverbergh, D De Graeve, ... Health Policy 106 (3), 284-290, 2012 | 18 | 2012 |
| Hospital supplements in Belgium: Price variation and regulation A Lecluyse, C Van de Voorde, D De Graeve, E Schokkaert, T Van Ourti Health policy 92 (2-3), 276-287, 2009 | 18 | 2009 |
| The out-of-pocket burden of chronic diseases: the cases of Belgian, Czech and German older adults V Kočiš Krůtilová, L Bahnsen, D De Graeve BMC Health Services Research 21, 1-13, 2021 | 17 | 2021 |
